US › Healthcare

Aptevo Therapeutics Inc (APVO)

US · Healthcare · Biotechnology

$4.09+3.54%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-6.7M
Profit YoY
-4.5%
EPS
$-6.41
EPS estimate
$-5.60

EPS came in at -6.41 against a street estimate of -5.60 — a miss of 14.5%.

Key statistics

Market cap
$5.1M
P/E
0.0
Forward P/E
3.9
P/B
0.44
Book value
$9.65
EPS (TTM)
$1,488.13
52-week high
$46.80
52-week low
$3.68
50-day MA
$4.60
200-day MA
$10.40
Beta
1.65

Analyst view

Analysts rate Aptevo Therapeutics Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $25.50.

Shareholding

Insiders
7.97%
Institutions
4.46%

Largest institutional holders

FundStake
GSA Capital Partners LLP1.58%
Geode Capital Management, LLC1.07%
Vanguard Capital Management, LLC1.02%
Vanguard Fiduciary Trust Co0.33%
UBS Group AG0.28%
Advisor Group Holdings, Inc.0.03%
SBI Securities Co Ltd0.01%
CWM, LLC duplicate0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Aptevo Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.